DaVita is trading higher today, supported by positive sentiment surrounding its Integrated Kidney Care business, which is projected to contribute roughly $20 million in adjusted operating income growth for 2026 through improved quality
scores and CMS program savings. The stock is also benefiting from continued investor attention regarding its significant backing by Berkshire Hathaway, which maintains a roughly 45% ownership stake. While the broader healthcare sector shows mixed performance among peers like HealthEquity and Encompass Health, DaVita's